Skip to main content

nomlabofusp

nomlabofusp: 2 clinical trials tracked.

nomlabofusp evidence translation

What we can confirm

2 tracked trials

No verified listed company relationship

What it means

AI will separate confirmed drug evidence from unknown company context.

What to watch

Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected

Prepared research question

What is verified about nomlabofusp, and what remains unknown?

Run cited research

Traceable citations · Unknowns marked

See linked entities and source evidence1 indications · 1 study sponsors

Related indications

Friedreich Ataxia
Clinical Trial Registry Records (2)

A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Subcutaneous Nomlabofusp in Subjects With Friedreich's Ataxia

NCT07778836Registry updated 2026-10-09·Phase 3·LRMR
Recruiting

Primary endpoint: Change from baseline in Upright Stability Score (USS) subscale E of modified Friedreich's Ataxia Rating Scale (mFARS) at Week 72 (Region-specific)

InterventionalRandomizedquadruple150 targetStarted 2026-10Completion 2029-124 sites · United StatesLarimar Therapeutics, Inc.

A Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneous Nomlabofusp in Adolescents and Children With Friedreich's Ataxia

NCT06681766Registry updated 2026-07-10·Phase 1·LRMR
Terminated

Primary endpoint: Number of AEs, TEAEs, related TEAEs, Grade 3/4 TEAEs, and SAEs

InterventionalRandomizedquadruple18 enrolledStarted 2024-12Completion 2025-041 site · United StatesLarimar Therapeutics, Inc.